Título:	Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia
Autor(es):	Ramos, Doralina do Amaral Rabello Araujo, Antonio Roberto Lucena Silva, Juliana Carvalho Rocha Alves Eira, Vinícius Burnett Aboud Souza da Vasconcellos, Maria Catarina Cals de Oliveira, Fábio Morato de Rêgo, Eduardo Magalhães Araujo, Felipe Saldanha de Pittella-Silva, Fabio
Afiliação do autor:	Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Patologia Molecular do Câncer
Assunto:	Leucemia linfocítica crônica (LLC) Histonas Metiltransferase Expressão gênica Citogenética
Data de publicação:	2015
Editora:	Elsevier
Referência:	RABELLO, Doralina do Amaral et al. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, [S.l.], v. 54, n. 1, p. 97-102, 2015. DOI: https://doi.org/10.1016/j.bcmd.2014.07.013.
Abstract:	EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness.
DOI:	https://doi.org/10.1016/j.bcmd.2014.07.013
Versão da editora:	https://www.sciencedirect.com/science/article/pii/S1079979614000928?via%3Dihub
Aparece nas coleções:	Artigos publicados em periódicos e afins

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.